Zevra Therapeutics, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Zevra Therapeutics, Inc. (ZVRA) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$420.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- Zevra Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$420.00K.
- Zevra Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$1.03M.
- Zevra Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $1.65M, a 121.45% increase year-over-year.
- Zevra Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $12.00K.
- Zevra Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was -$1.40M, a 306.97% decline from fiscal 2024.
- Zevra Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $674.00K.
- Zevra Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$156.00K, a 238.05% decline from fiscal 2022.
- Zevra Therapeutics, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $113.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$420.00K 10-Q · filed 2026-08-05 | -$1.45M 10-Q · filed 2026-08-05 | $199.00K derived: sum of 3 quarters · filed 2026-08-05 | $211.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.03M 10-Q · filed 2026-08-05 | $619.00K derived: sum of 2 quarters · filed 2026-08-05 | $631.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.66M derived: sum of 2 quarters · filed 2026-03-09 | -$682.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.40M 10-K · filed 2026-03-09 |
| 2025-09-30 | $12.00K 10-Q · filed 2025-11-05 | -$2.33M derived: sum of 2 quarters · filed 2026-08-05 | -$3.05M 10-Q · filed 2025-11-05 | -$2.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$2.35M 10-Q · filed 2026-08-05 | -$3.06M 10-Q · filed 2026-08-05 | -$2.31M derived: sum of 3 quarters · filed 2026-08-05 | -$2.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$713.00K 10-Q · filed 2026-08-05 | $33.00K derived: sum of 2 quarters · filed 2026-08-05 | -$503.00K derived: sum of 3 quarters · filed 2026-08-05 | -$223.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2024-12-31 | $746.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $210.00K derived: sum of 2 quarters · filed 2026-03-09 | $490.00K derived: sum of 3 quarters · filed 2026-03-09 | $674.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | -$536.00K 10-Q · filed 2025-11-05 | -$256.00K derived: sum of 2 quarters · filed 2025-11-05 | -$72.00K 10-Q · filed 2025-11-05 | $105.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $280.00K 10-Q · filed 2025-11-05 | $464.00K 10-Q · filed 2025-08-12 | $641.00K derived: sum of 3 quarters · filed 2025-11-05 | $646.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-03-31 | $184.00K 10-Q · filed 2025-11-05 | $361.00K derived: sum of 2 quarters · filed 2025-11-05 | $366.00K derived: sum of 3 quarters · filed 2025-11-05 | $204.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2023-12-31 | $177.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $182.00K derived: sum of 2 quarters · filed 2025-03-12 | $20.00K derived: sum of 3 quarters · filed 2025-03-12 | -$156.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $5.00K 10-Q · filed 2024-11-13 | -$157.00K derived: sum of 2 quarters · filed 2024-11-13 | -$333.00K 10-Q · filed 2024-11-13 | -$421.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$162.00K 10-Q · filed 2024-11-13 | -$338.00K 10-Q · filed 2024-08-14 | -$426.00K derived: sum of 3 quarters · filed 2024-11-13 | -$225.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-03-31 | -$176.00K 10-Q · filed 2024-11-13 | -$264.00K derived: sum of 2 quarters · filed 2024-11-13 | -$63.00K derived: sum of 3 quarters · filed 2024-11-13 | -$63.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2022-12-31 | -$88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $113.00K derived: sum of 2 quarters · filed 2024-04-01 | $113.00K derived: sum of 3 quarters · filed 2024-04-01 | $113.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | $201.00K 10-K · filed 2024-04-01 | $201.00K derived: sum of 2 quarters · filed 2024-04-01 | $201.00K 10-Q · filed 2023-11-07 | $201.00K derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $0.00 derived: sum of 3 quarters · filed 2023-08-14 | $0.00 derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-15 | $0.00 derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-07 | $0.00 10-K · filed 2023-03-07 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |